Taipei, Taiwan, 03 December 2025 — Lotus Pharmaceuticals (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, today announced the successful completion of its acquisition of Alvogen US (the “Transaction”). All required closing conditions and regulatory approvals have been satisfied.
The transaction marks a significant step in Lotus’ long-term strategy to scale its global specialty pharmaceutical platform. By bringing Alvogen US into the Group, Lotus acquires a fully integrated U.S. operating base that enhances capabilities across R&D, manufacturing, commercial operations, and supporting functions such as legal and regulatory affairs. The acquisition also broadens Lotus’ specialty portfolio and extends its global reach.
Integration activities will now proceed, with a focus on continuity, and close alignment across operations and teams. Lotus expects the combination to accelerate portfolio expansion and support sustainable growth in Lotus’ core markets.
Leadership Comments
Róbert Wessman, Chairman of Lotus Pharmaceuticals, commented:
“Acquisition of Alvogen US marks a major milestone for Lotus. It meaningfully strengthens our global footprint and broadens our specialty portfolio, while reinforcing the diversified growth engine we have been building. We are excited to welcome the Alvogen US team and look forward to advancing our next phase of growth together.”
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercialising both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com